Suppr超能文献

人类溶酶体β-半乳糖苷酶与其保护蛋白之间的关系。

The relation between human lysosomal beta-galactosidase and its protective protein.

作者信息

Hoogeveen A T, Verheijen F W, Galjaard H

出版信息

J Biol Chem. 1983 Oct 25;258(20):12143-6.

PMID:6415049
Abstract

Cultured skin fibroblasts from patients with the lysosomal storage disease galactosialidosis lack a 54-kDa protein which is a precursor of 32-kDa and 20-kDa proteins, which immunoprecipitate with human anti-beta-galactosidase antiserum. The lack of a 32-kDa "protective protein" results in a combined deficiency of beta-galactosidase and sialidase. The mechanism of protection of lysosomal beta-galactosidase against proteolytic degradation is elucidated by sucrose density gradient centrifugation and immunoprecipitation studies. In normal fibroblasts at the low intralysosomal pH, more than 85% of beta-galactosidase exists as a high molecular weight (600-700 kDa) multimer and about 10% as a monomer of 64-kDa. In mutant cells from galactosialidosis patients, the residual enzyme activity, about 10%, is present as a monomer and no multimer exists. After addition of the 54-kDa precursor form of the protective protein, the density pattern of beta-galactosidase in galactosialidosis cells is normalized. Immunoprecipitation studies after sucrose density gradient centrifugation on homogenate and on purified beta-galactosidase from normal fibroblasts show that the protective protein is associated only with the multimeric form of beta-galactosidase. We propose that intralysosomal protection against proteolysis of beta-galactosidase and sialidase is accomplished by aggregation into a high molecular weight complex consisting of multimeric beta-galactosidase, sialidase, and protective protein. The genetic deficiency of the latter, as in galactosialidosis, results in a rapid degradation of monomeric beta-galactosidase and a loss of sialidase activity.

摘要

来自溶酶体贮积病半乳糖唾液酸贮积症患者的培养皮肤成纤维细胞缺乏一种54 kDa的蛋白质,该蛋白质是32 kDa和20 kDa蛋白质的前体,可与人抗β-半乳糖苷酶抗血清发生免疫沉淀。缺乏32 kDa的“保护蛋白”会导致β-半乳糖苷酶和唾液酸酶联合缺乏。通过蔗糖密度梯度离心和免疫沉淀研究阐明了溶酶体β-半乳糖苷酶免受蛋白水解降解的保护机制。在正常成纤维细胞中,在低溶酶体内pH值下,超过85%的β-半乳糖苷酶以高分子量(600 - 700 kDa)多聚体形式存在,约10%以64 kDa的单体形式存在。在半乳糖唾液酸贮积症患者的突变细胞中,约10%的残余酶活性以单体形式存在,不存在多聚体。添加保护蛋白的54 kDa前体形式后,半乳糖唾液酸贮积症细胞中β-半乳糖苷酶的密度模式恢复正常。对正常成纤维细胞匀浆和纯化的β-半乳糖苷酶进行蔗糖密度梯度离心后的免疫沉淀研究表明,保护蛋白仅与β-半乳糖苷酶的多聚体形式相关。我们提出,溶酶体内对β-半乳糖苷酶和唾液酸酶的蛋白水解保护是通过聚集形成由多聚体β-半乳糖苷酶、唾液酸酶和保护蛋白组成的高分子量复合物来实现的。后者的基因缺陷,如在半乳糖唾液酸贮积症中,会导致单体β-半乳糖苷酶的快速降解和唾液酸酶活性的丧失。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验